Galectin Therapeutics has published new preclinical data demonstrating that its galectin-inhibiting drugs — GR-MD-02 and GM-CT-01 — demonstrate positive therapeutic effects on nonalcoholic steatohepatitis (NASH, or fatty liver disease) with fibrosis. The results were published in the article, “Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors,” in the peer-reviewed, open-access journal PLOS ONE. In the study, NASH-induced mice were treated with GM-CT-01 ...